Bayer (DE:BAYN)
XETRA:BAYN
Top Page
Bayer
(XETRA:BAYN)
Select Model
Select Model
Rating:48Neutral
Price Target:
€40.00
▲(4.55% Upside)
Action:ReiteratedDate:03/06/26
The score is primarily held back by declining revenue and persistent net losses alongside elevated leverage, even though operating margins improved and cash flow remains positive. Technicals add further pressure due to bearish short-term trend indicators (below 20/50-day averages and negative MACD), while valuation is only mildly supportive given a negative P/E and a high dividend yield with sustainability risk.
Positive Factors
Consistent cash generation
Bayer has sustained positive operating and free cash flow even while reporting net losses. That durable cash generation supports ongoing R&D, manufacturing and working-capital needs, funding operations and strategic initiatives without immediate reliance on equity issuance or asset sales.
Negative Factors
Declining revenues with sharp 2025 drop
Sustained revenue declines, capped by a steep fall in 2025, indicate weakening demand or loss of market share. Persistent top-line contraction undermines operating leverage, reduces reinvestment capacity and raises the bar for new product launches to restore long-term growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent cash generation
Bayer has sustained positive operating and free cash flow even while reporting net losses. That durable cash generation supports ongoing R&D, manufacturing and working-capital needs, funding operations and strategic initiatives without immediate reliance on equity issuance or asset sales.
Read all positive factors
Bayer (BAYN) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€37.59B
Dividend Yield0.31%
Average Volume (3M)2.24M
Price to Earnings (P/E)―
Beta (1Y)1.01
Revenue Growth-1.87%
EPS Growth77.51%
CountryDE
Employees90,587
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)0.62
Shares Outstanding982,424,100
10 Day Avg. Volume2,239,372
30 Day Avg. Volume2,240,598
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)1.40
Price to Sales (P/S)0.80
P/FCF Ratio17.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€45.30Price Target Upside18.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)4.36
Revenue Forecast (FY)€45.46B
Bayer Business Overview & Revenue Model
Company Description
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily ...
How the Company Makes Money
Bayer makes money mainly by selling products across its three operating segments. (1) Pharmaceuticals: Revenue is generated from prescription drug sales to wholesalers, pharmacies, hospitals, and healthcare providers, typically with pricing and vo...
Bayer Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
46
Neutral
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 45.58B | 46.61B | 47.64B | 50.74B | 44.08B |
| Gross Profit | 26.98B | 25.34B | 27.89B | 30.87B | 27.27B |
| EBITDA | 11.01B | 8.53B | 12.34B | 12.19B | 11.67B |
| Net Income | -3.62B | -2.55B | -2.94B | 4.15B | 1.00B |
Balance Sheet | |||||
| Total Assets | 110.61B | 110.85B | 116.26B | 124.88B | 120.24B |
| Cash, Cash Equivalents and Short-Term Investments | 7.86B | 8.09B | 10.59B | 10.15B | 7.74B |
| Total Debt | 37.44B | 40.81B | 44.79B | 41.65B | 39.53B |
| Total Liabilities | 84.54B | 78.81B | 83.18B | 85.95B | 87.07B |
| Stockholders Equity | 25.95B | 31.91B | 32.93B | 38.77B | 33.02B |
Cash Flow | |||||
| Free Cash Flow | 2.08B | 4.59B | 2.37B | 4.14B | 2.48B |
| Operating Cash Flow | 4.57B | 7.37B | 5.12B | 7.09B | 5.09B |
| Investing Cash Flow | -1.61B | 164.00M | -4.01B | -2.38B | 855.00M |
| Financing Cash Flow | -2.19B | -7.18B | -679.00M | -4.22B | -5.64B |
Bayer Technical Analysis
Neutral
38.26
Price Trends
42.34
Negative
38.03
Positive
32.76
Positive
Market Momentum
-1.01
Negative
41.51
Neutral
36.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BAYN, the sentiment is Neutral. The current price of 38.26 is below the 20-day moving average (MA) of 38.65, below the 50-day MA of 42.34, and above the 200-day MA of 32.76, indicating a neutral trend. The MACD of -1.01 indicates Negative momentum. The RSI at 41.51 is Neutral, neither overbought nor oversold. The STOCH value of 36.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:BAYN.
Bayer Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | €16.35B | 21.99 | 7.77% | 1.08% | 1.83% | 21.36% | |
65 Neutral | €2.18B | 26.13 | 6.77% | 1.50% | 7.82% | -19.80% | |
60 Neutral | €1.41B | 26.77 | 4.19% | 0.20% | 1.16% | -43.53% | |
57 Neutral | €46.50B | 24.47 | 4.82% | 5.16% | -2.94% | -45.21% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | €1.41B | -63.32 | 4.98% | ― | -18.82% | -113.85% | |
48 Neutral | €37.59B | -10.04 | -12.24% | 0.31% | -1.87% | 77.51% |
* General Sector Average
DE:BAYN
Bayer
38.26
16.30
74.19%
DE:BAS
BASF SE
52.10
8.53
19.58%
DE:BEI
Beiersdorf
74.80
-43.60
-36.82%
DE:BIO
Biotest
39.20
-3.00
-7.11%
DE:AFX
Carl Zeiss Meditec
24.32
-34.95
-58.96%
DE:COP
CompuGroup Medical
26.82
4.27
18.93%
Bayer Corporate Events
Regulatory Filings and Compliance
Bayer Supervisory Board Member Buys Shares Under Board Purchase Commitment
Positive
Mar 11, 2026
Bayer disclosed a managers’ transaction under EU market abuse rules, reporting that supervisory board member Kimberly Mathisen purchased Bayer shares on March 6, 2026 via the Xetra trading platform. The acquisition, totaling €56,550 at...
Other
Bayer Board Member Hartmann Buys Shares Worth About €486,000
Positive
Mar 9, 2026
Bayer disclosed that Management Board member Dr. Judith Hartmann purchased Bayer shares on March 5, 2026 via the Xetra trading platform, in line with the board’s commitment to buy company stock. The series of transactions, executed at prices...
Regulatory Filings and Compliance
Bayer Discloses Insider Share Purchase Linked to Supervisory Board Member
Positive
Mar 9, 2026
Bayer disclosed a managers’ transaction involving The Herbert-Schechter Trust, which is closely associated with supervisory board member Lori Schechter, purchasing Bayer shares. The transaction, executed on March 6, 2026 via Xetra, totaled &...
Business Operations and StrategyRegulatory Filings and Compliance
Bayer CEO Anderson Buys Nearly €790,000 in Shares Under Board Commitment
Positive
Mar 9, 2026
Bayer disclosed a managers’ transaction involving CEO and board member William N. Anderson, who, together with his wife via a joint account, purchased Bayer shares on the Xetra exchange. The acquisition, worth about €789,585 at a price...
Regulatory Filings and Compliance
Bayer Supervisory Board Member Buys Shares in Disclosed Manager Transaction
Positive
Mar 6, 2026
Bayer has disclosed a manager’s transaction under EU market abuse rules, reporting that supervisory board member Prof. Dr. Norbert Winkeljohann purchased Bayer shares on March 5, 2026. The transaction, executed on the Xetra trading platform ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.